Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

• Published in: The New England journal of medicine Vol. 385; no. 12; pp. 1091 - 1103
• Main Authors: Sartor, Oliver, de Bono, Johann, Chi, Kim N, Fizazi, Karim, Herrmann, Ken, Rahbar, Kambiz, Tagawa, Scott T, Nordquist, Luke T, Vaishampayan, Nitin, El-Haddad, Ghassan, Park, Chandler H, Beer, Tomasz M, Armour, Alison, Pérez-Contreras, Wendy J, DeSilvio, Michelle, Kpamegan, Euloge, Gericke, Germo, Messmann, Richard A, Morris, Michael J, Krause, Bernd J
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 16.09.2021
• Subjects: Adverse events; Aged; Aged, 80 and over; Androgen receptors; Androgens; Antigens; Biomarkers; Cancer therapies; Castration; Chemotherapy; Combined Modality Therapy; Computed tomography; Dipeptides - therapeutic use; Disease control; Drug dosages; Drug withdrawal; FDA approval; Gallium; Hematology; Heterocyclic Compounds, 1-Ring - therapeutic use; Humans; Immunotherapy; Kallikreins - antagonists & inhibitors; Lutetium - adverse effects; Lutetium - therapeutic use; Magnetic resonance imaging; Male; Medical prognosis; Metastases; Metastasis; Microenvironments; Middle Aged; Oncology; Pain; Patients; Positron-Emission Tomography; Prostate - diagnostic imaging; Prostate cancer; Prostate Disease; Prostate Disease General; Prostate-Specific Antigen - antagonists & inhibitors; Prostate-Specific Antigen - therapeutic use; Prostatic Neoplasms, Castration-Resistant - diagnostic imaging; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - mortality; Prostatic Neoplasms, Castration-Resistant - radiotherapy; Quality of life; Radiation; Radioisotopes - adverse effects; Radioisotopes - therapeutic use; Radium; Survival Analysis; Treatments in Oncology; Urology
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2107322

Guiding the beta-emitting isotope lutetium-177 to prostate cancer lesions with the prostate-specific membrane antigen–targeted radioligand 177 Lu-PSMA-617 plus using standard care was compared with standard care in patients with metastatic castration-resistant prostate cancer. The radioligand therapy prolonged progression-free and overall survival. Adverse effects were more common, but quality of life was maintained.